It’s a special day @MSKCancerCenter. We honor David Rubenstein Awardee Marina Pasca di Magliano @Pasca_Lab@UMRogelCancer. Marina is a brilliant scientist who lights the way for our field, and a treasured mentor + colleague to so many. Congrats Marina + her team! 💜
Are you passionate about metastasis and interested in starting your laboratory here @FredHutch_Met_X? Here's your opportunity - deadline's on Monday!!!
https://t.co/cOnX1dLvFu
Our @Nature paper is out!
It's been known for a while that long-term dietary habits can affect how our immune system behaves. But what about much briefer changes in diet?
In mice, we found that even a few days of dietary change (think cheat days...or perhaps salad Sundays) at the onset of inflammation can profoundly alter disease severity and establish lasting inflammatory memory in tissues, even after the diet changes back.
https://t.co/AO5fjQjmwR
This work was led by two extraordinarily dedicated and inexhaustible members of our lab: former graduate student @OwenJ457 and former technician John Tayeri. It was also an exercise in collaborative science as many labs @UCSF and @Stanford came together to bring this over the finish line - special thanks to @gardnerlabUCSF, @Molofsky_lab, @alexis_combes, @Treg_Mike. Deeply grateful to everyone who contributed!
So honored to join this club and to know my peers value my impact. But the celebration and honor is even bigger knowing I join together with @rosslevinemd , our CSO whose impact on medicine is truly great.
There is an opening for a postdoc in my laboratory. The aim of the post is to develop and use novel methodologies for mass spectrometry and phosphoproteomics analysis in complex multicellular environments. https://t.co/PyDZtId3sR
1/ Most genes and variants matter somewhere but look silent in any one cell model. Can we build conditions that reveal phenotypes? With @kanishkadey, we engineer cell states to expose hidden disease biology and trace how genetic risk reaches disease genes. https://t.co/pUHPPjxTkX
🎉Our paper on #PDAC and #Pancreatitis organoid multistroma #cocultures is on the cover of @NatureCellBio! Congratulations to the whole lab!!
Almost 10 years (🤯) after my postdoc paper in @JExpMed, here we are again!! So poetic!
https://t.co/b3nV2mvYOe
After many years of effort, deliberation, excitement, angst, joy, and Wednesday afternoon lab lunches, our group's first manuscript on cachexia, led by Venise Jan Castillon, Amy Xie, and really our whole lab https://t.co/PizrA8NyaU @NatureMedicine
💡 What sets the size of a germinal center? — why lymphatics of course 😉
Our new study with Carla Nowosad reveals how lymphatic remodeling constrains germinal center growth and shapes the quality of the antibody response. @ImmunityCP@nyugrossman
https://t.co/g1RXqZ1tc7
Very happy to share our new paper in Nature Cancer. This project started with a simple question: what drives the early loss of adipose tissue during pancreatic cancer cachexia?
Great collaboration with @CentralParkWMD@MarcHilmi@EileenMOReilly@ciacobu@schoenfeld_j@MckerrowWilson & an incredible team 👇👇👇
https://t.co/tPncGt4zX4
The broader immunologic point from this work is the distinction between systemic activation and tissue-effective immunity. Neoantigen recognition by specific T-cell receptor, clonal expansion and spatial context all matter and the tumor ecosystem can determine whether a T-cell response becomes effective. From studies like this we will learning more about the fundamental rules of T-cell engagement in cancer and how to translate for precision immunotherapies, such as cancer vaccines, to help more patients.
@MSKCancerCenter
🧵 1/10 The arc: POLAR - MDF – TIE
Pancreatic cancer is profoundly resistant to immune checkpoint inhibitors.
Yet, POLAR (pembrolizumab plus olaparib) trial showed that a subset of patients, especially with HRD (gBRCA2/1m or gPALB2m) tumors, can achieve remarkably durable control.
That led us to two questions:
#1 👆🏼what makes these tumors immunogenic?
#2 ✌️what makes that immunity actually work?
👑 #2. POLAR TIE @biorxivpreprint
https://t.co/IAQpmSzBE0
#1. MDF https://t.co/9vqCZF8Z6i
#0. POLAR @NatureMedicine https://t.co/UtCD1C7i4R
#cancer #immunotherapy #PancreaticCancer #ICI #BRCA #HRD #3episodes @MSKCancerCenter@MSK_DeptOfMed@CpcrMsk@ldiaz1971@debschrag@PanCAN@oncodaily@OncoDailyGI@OncoAlert@OncBrothers@brunolarvol
Pancreatic tumors are highly heterogeneous and immunosuppressive. But is immune resistance imposed across the whole tumor - or built locally by distinct cancer-cell states?
I’m incredibly excited to share our new paper, now out in @Nature! 🎉
https://t.co/jtEUKKFrBu
(1/7)
Three years ago, my lab at @MSKCancerCenter set out to see if we could harness AI for new therapeutic proteins.
Today in @natBME, our first step in developing these AI-designed molecules as anti-tumor therapies is online.
Read more here: 1/n https://t.co/eb2ufazEKC
🥳Happy to share our latest manuscript - out today in @NatureCellBio.
💜 Congrats and thanks to @Wenlong_Li1 and @Munta04, the whole lab, our collaborators and the funders that supported this important and beautiful 🤩 work!
Hope you enjoy the read!
https://t.co/b3nV2mvYOe